G P Luyten
Overview
Explore the profile of G P Luyten including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
322
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Eskens F, Awada A, Cutler D, De Jonge M, Luyten G, Faber M, et al.
J Clin Oncol
. 2001 Feb;
19(4):1167-75.
PMID: 11181683
Purpose: A single-agent dose-escalating phase I and pharmacokinetic study on the farnesyl transferase inhibitor SCH 66336 was performed to determine the safety profile, maximum-tolerated dose, and recommended dose for phase...
2.
Naus N, van Drunen E, de Klein A, Luyten G, Paridaens D, Alers J, et al.
Genes Chromosomes Cancer
. 2001 Feb;
30(3):267-73.
PMID: 11170284
Several nonrandom recurrent chromosomal changes are observed in uveal melanoma. Some of these abnormalities, e.g., loss of chromosome 3, gain of the q arm of chromosome 8, and chromosome 6...
3.
Budo C, Hessloehl J, Izak M, Luyten G, Menezo J, Sener B, et al.
J Cataract Refract Surg
. 2000 Sep;
26(8):1163-71.
PMID: 11008043
Purpose: To assess the Artisan intraocular lens to correct myopia in phakic eyes. Setting: European multicenter study sponsored by Ophtec BV, Groningen, The Netherlands. Methods: In this prospective multicenter clinical...
4.
Naus N, Zuidervaart W, Rayman N, Slater R, van Drunen E, Ksander B, et al.
Int J Cancer
. 2000 Jun;
87(1):151-3.
PMID: 10861467
No abstract available.
5.
Wijers O, Levendag P, Luyten G, Bakker B, Freling N, Woudstra E
Strahlenther Onkol
. 1999 Feb;
175(1):21-7.
PMID: 9951514
Case Report: A case history of unanticipated radiation-induced bilateral optic neuropathy, 18 months after induction chemotherapy and radiation therapy for a locally advanced nasopharyngeal carcinoma, is presented. Retrospective reanalysis of...
6.
Luyten G, Van der Spek C, BRAND I, Sintnicolaas K, de Waard-Siebinga I, Jager M, et al.
Melanoma Res
. 1998 Mar;
8(1):11-6.
PMID: 9508371
In order to determine the possible use of uveal melanoma cell lines as stimulators in immunotherapy, we evaluated the expression of the human genes for MAGE-1, -2 and -3, gp100...
7.
van der Torren K, Luyten G
Arch Ophthalmol
. 1998 Mar;
116(2):256-7.
PMID: 9488289
No abstract available.
8.
van der Pol J, Blom D, Flens M, Luyten G, de Waard-Siebinga I, Koornneef L, et al.
Invest Ophthalmol Vis Sci
. 1997 Dec;
38(12):2523-30.
PMID: 9375571
Purpose: Metastatic uveal melanoma is strongly resistant to chemotherapy, and multidrug resistance (MDR) may be involved. To investigate the role of MDR, the presence of the MDR-associated proteins P-glycoprotein (Pgp),...
9.
Blom D, Goslings W, de Waard-Siebinga I, Luyten G, Claas F, Gorter A, et al.
J Interferon Cytokine Res
. 1997 Dec;
17(11):695-700.
PMID: 9402107
Tumor cells are protected from antibody-dependent complement-mediated lysis by membrane-bound regulators of complement activation (m-RCA). m-RCA are expressed on uveal melanoma cells. We determined whether cytokine treatment affects expression of...
10.
Blom D, Luyten G, Mooy C, Kerkvliet S, Zwinderman A, Jager M
Invest Ophthalmol Vis Sci
. 1997 Aug;
38(9):1865-72.
PMID: 9286277
Purpose: Because the expression of human leukocyte antigen (HLA) antigens is important for immunologic recognition of tumor cells, we determined expression of locus-specific HLA class I antigens in uveal melanoma...